Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma Pharmaceutical TechnologyEarly data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca's ESOT-01.HematologyRead full story pharminent June 2, 2026 (Last updated: June 3, 2026) Pharmaceutical Technology Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO26: In vivo oncology approaches continue to show promiseNext: Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
